Guardant Health Inc

-2.23 (-1.38%)
4:25:00 PM EDT: $159.00 -0.83 (-0.52%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)15.77B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$76.26 Million
Adjusted EPS-$0.56
See more estimates
10-Day MA$156.42
50-Day MA$130.07
200-Day MA$100.84
See more pivots

Guardant Health, Inc. Stock, NASDAQ:GH

United States of America
Phone: 855-698-8887
Number of Employees: 454


Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications. It also provides LUNAR-1 for minimal residual disease and recurrence detection in cancer survivors. In addition, the company is developing LUNAR-2 for early detection of cancer in higher risk individuals. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical trial referral, and liquid biopsy testing development and support services to biopharmaceutical companies and medical institutions. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California.